xl-250

N/A

Report date: 2025/03/20 14:41:44

Base Information

Drug Namexl-250
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate +[4] 
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsRNA polymerase II inhibitors
TargetsRNA polymerase IIReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesXL-protein GmbH
China Registration ClassN/A

Develop Information

Active CompaniesHeidelberg Pharma AGXL-protein GmbH
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A